Dodick D.W. Loder E.W. Manack Adams A. et al.

Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the chronic migraine epidemiology and outcomes (CaMEO) study.

Headache. 56: 821-834Steiner T.J. Stovner L.J. Jensen R. et al.

Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019.

J Headache Pain. 21: 137

GBD 2016: still no improvement in the burden of Migraine.

Lancet Neurol. 17: 929-930Natoli J.L. Manack A. Dean B. et al.

Global prevalence of chronic migraine: a systematic review.

Cephalalgia. 30: 599-609Buse D.C. Manack A.N. Fanning K.M. et al.

Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American migraine prevalence and Prevention Study.

Headache. 52: 1456-1470Bigal M.E. Serrano D. Buse D. et al.

Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.

Headache. 48: 1157-1168Burch R.C. Buse D.C. Lipton R.B.

Migraine.

Neurol Clin. 37: 631-649Manack A. Buse D.C. Serrano D. et al.

Rates, Predictors, and consequences of remission from chronic migraine to episodic migraine.

Neurology. 76: 711-718

Headache classification committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd Edition.

Cephalalgia. 38: 1-211

Chronic migraine: risk factors, mechanisms and treatment.

Nat Rev Neurol. 12: 455-464Buse D.C. Greisman J.D. Baigi K. et al.

Migraine progression: a systematic review.

Headache. 59: 306-338

Seeds for success: lifestyle Management in Migraine.

Cleve Clin J Med. 86: 741-749Lipton R.B. Fanning K.M. Serrano D. et al.

Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine.

Neurology. 84: 688-695Lipton R.B. Stewart W.F. Stone A.M. et al.

Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study: a randomized trial.

JAMA. 284: 2599-2605Goadsby P.J. Wietecha L.A. Dennehy E.B. et al.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of Migraine.

Brain. 142: 1894-1904Kuca B. Silberstein S.D. Wietecha L. et al.

Lasmiditan is an effective acute treatment for migraine.

Neurology. 91: e2222-e2232Wilbraham D. Berg P.H. Tsai M. et al.

Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study.

J Clin Pharmacol. 60: 495-504Rau J.C. Navratilova E. Oyarzo J. et al.

Evaluation of ly573144 (lasmiditan) in a preclinical model of medication overuse headache.

Cephalalgia. 40: 903-912Lipton R.B. Dodick D.W. Ailani J. et al.

Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of Migraine.

JAMA. 322: 1887Croop R. Goadsby P.J. Stock D.A. et al.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of Migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

The Lancet. 394: 737-745Dodick D.W. Lipton R.B. Ailani J. et al.

Ubrogepant for the treatment of Migraine.

N Engl J Med. 381: 2230-2241Lipton R.B. Dodick D.W. Goadsby P.J. et al.

Within-person analysis of ubrogepant treatment of mild versus moderate-severe headache pain during a phase 3 long-term safety extension trial (S31.006).

Neurology. 98: 167Berman G. Croop R. Kudrow D. et al.

Safety of Rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for Migraine. Headache.

J Head Face Pain. 60: 1734-1742Mulder I.A. Li M. Vries T. et al.

Anti-migraine calcitonin gene–related peptide receptor antagonists worsen cerebral ischemic outcome in mice.

Ann Neurol. 88: 771-784Chowdhury D. Bansal L. Duggal A. et al.

TOP-PRO Study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine.

Cephalalgia. 42: 396-408Jackson J.L. Kuriyama A. Kuwatsuka Y. et al.

Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.

PLoS One. 14: e0212785Lai K.L. Niddam D.M. Fuh J.L. et al.

Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial.

Acta Neurol Scand. 135: 476-483Sánchez-Rodríguez C. Sierra A. Planchuelo-Gómez A. et al.

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study.

Scientific Rep. 11: 3846

Preventive migraine treatment.

Continuum. 21: 973-989Ailani J. Burch R.C. Robbins M.S.

The american headache society consensus statement: update on integrating new migraine treatments into clinical practice.

Headache. 61: 1021-1039

Chronic migraine.

BMJ. 348https://doi.org/10.1136/bmj.g1416Diener H.-C. Dodick D. Goadsby P. et al.

Chronic migraine--classification, characteristics and Treatment.

Nat Rev Neurol. 8: 162-171Silberstein S.D. Lipton R. Dodick D. et al.

Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Headache. 47: 170-180Diener H.C. Bussone G. Oene J.V. et al.

Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Cephalalgia. 27: 814-823

Preventive migraine treatment.

Continuum. 27: 613-632

Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.

Neurol Sci. 31: 23-28Yurekli V.A. Akhan G. Kutluhan S. et al.

The effect of sodium valproate on chronic daily headache and its subgroups.

J Headache Pain. 9: 37-41

Gabapentin in the prophylaxis of chronic daily headache.

Neurology. 61: 1753-1759Calandre E.P. Garcia-Leiva J.M. Rico-Villademoros F. et al.

Pregabalin in the treatment of chronic migraine: an open-label study.

Clin Neuropharmacol. 33: 35-39Belvis R. Aceituno A. Martinez-Corral M.

Zonisamide is effective in the preventive therapy of chronic migraine: doc 551.

J Headache Pain. 14: 1Villani V. Ciuffoli A. Prosperini L. et al.

Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study.

Headache. 51: 287-291

Zonisamide for migraine prophylaxis in patients refractory to topiramate.

Clin Neuropharmacol. 32: 103-106Jion Y.I. Raff A. Grosberg B.M. et al.

The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension.

Headache. 55: 161-166

Amitriptyline in the prophylactic treatment of migraine and chronic daily headache.

Headache. 51: 33-51Doyle Strauss L. Weizenbaum E. Loder E.W. et al.

Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study.

Headache. 56: 1626-1634

An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache.

J Clin Psychiatry. 69: 1449-1454Young W.B. Bradley K.C. Anjum M.W. et al.

Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study.

Headache. 53: 1430-1437Dorosch T. Ganzer C.A. Lin M. et al.

Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults.

Curr Pain Headache Rep. 23: 85-88

Other preventive anti-migraine treatments: ACE inhibitors, ARBS, calcium channel blockers, serotonin antagonists, and NMDA receptor antagonists.

Curr Treat Options Neurol. 21: 17Stovner L.J. Linde M. Gravdahl G.B. et al.

A comparative study of Candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study.

Cephalalgia. 34: 523-532Messina R. Lastarria Perez C.P. Filippi M. et al.

Candesartan in migraine prevention: results from a retrospective real-world study.

J Neurol. 267: 3243-3247

Atenolol in the Prophylaxis of Chronic Migraine: a 3-Month Open-Label Study.

SpringerPlus. 2: 479Silberstein S.D. Peres M.F.P. Hopkins M.M. et al.

Olanzapine in the treatment of refractory migraine and chronic daily headache.

Headache. 42: 515-518Saper J.R. Lake III, A.E. Cantrell D.T. et al.

Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Headache. 42: 470-482Huang L. Bocek M. Jordan J.K. et al.

Memantine for the prevention of primary headache disorders.

Ann Pharmacother. 48: 1507-1511Goadsby P.J. Dodick D.W. Ailani J. et al.

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2B/3 trial.

Lancet Neurol. 19: 727-737

Abbvie. Press release. AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™) Data for the Preventive Treatment of Chronic Migraine.

() ()Silberstein S.D. Holland S. Freitag F. et al.

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults.

Neurology. 78: 1337-1345Simpson D.M. Hallett M. Ashman E.J. et al.

Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache.

Neurology. 86: 1818-1826

Therapeutic novelties in Migraine: new drugs, new hope?.

J Headache Pain. 20: 37Brandes J.L. Diener H.-C. Dolezil D. et al.

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.

Cephalalgia. 40: 28-38Ashina M. Goadsby P.J. Reuter U. et al.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Cephalalgia. 39: 1455-1464

History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from Translational Research to treatment.

Headache. 58: 238-275

Raynaud's phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists.

Headache. 59: 1360-1364Breen I.D. Brumfield C.M. Patel M.H. et al.

Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with raynaud phenomenon.

JAMA Netw Open. 4: e217934Schwedt T. Reuter U. Tepper S. et al.

Early onset of efficacy with erenumab in patients with episodic and chronic migraine.

J Headache Pain. 19: 92

Headache in pregnancy and lactation.

Continuum (Minneap Minn). 28: 72-92

Safety and tolerability of preventive treatment options for chronic migraine.

Expert Opin Drug Saf. 20: 1523-1533Lipton R.B. Goadsby P.J. Smith J. et al.

Efficacy and safety of eptinezumab in patients with chronic migraine.

Neurology. 94: e1365-e1377Ray J.C. Walter S. Rapoport A.M. et al.

Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects.

J Neurol Neurosurg Psychiatr. 92: 1325-1334Dodick D.W. Lipton R.B. Silberstein S. et al.

Eptinezumab for prevention of chronic migraine: a randomized phase 2B clinical trial.

Cephalalgia. 39: 1075-1085Dodick D.W. Ashina M. Brandes J.L. et al.

Arise: a phase 3 randomized trial of erenumab for episodic migraine.

Cephalalgia. 38: 1026-1037Goadsby P.J. Reuter U. Hallström Y. et al.

A controlled trial of erenumab for episodic migraine.

N Engl J Med. 377: 2123-2132Tepper S. Ashina M. Reuter U. et al.

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

Lancet Neurol. 16: 425-434Kudrow D. Pascual J. Winner P.K. et al.

Vascular safety of erenumab for migraine prevention.

Neurology. 94: 1052Lipton R.B. Tepper S.J. Reuter U. et al.

Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study.

Neurology. 92: e2250-e2260Dodick D.W. Silberstein S.D. Bigal M.E. et al.

Effect of fremanezumab compared with placebo for prevention of episodic migraine.

JAMA. 319: 1999Silberstein S.D. Dodick D.W. Bigal M.E. et al.

Fremanezumab for the preventive treatment of chronic migraine.

N Engl J Med. 377: 2113-2122Detke H.C. Goadsby P.J. Wang S. et al.

Galcanezumab in chronic migraine.

Neurology. 91: e2211-e2221Skljarevski V. Oakes T.M. Zhang Q. et al.

Effect of different doses of galcanezumab vs placebo for episodic migraine prevention.

JAMA Neurol. 75: 187Stauffer V.L. Dodick D.W. Zhang Q. et al.

Evaluation of galcanezumab for the prevention of episodic migraine.

JAMA Neurol. 75: 1080Frampton J.E. OnabotulinumtoxinA S.S.

A review in the prevention of chronic migraine.

Drugs. 78: 589-600Diener H.C. Dodick D.W. Turkel C.C. et al.

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Headache. 50: 921-936Silberstein S.D. Dodick D.W. Aurora S.K. et al.

Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

J Neurol Neurosurg Psychiatr. 86: 996-1001Burstein R. Zhang X.C. Levy D. et al.

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains.

Cephalalgia. 34: 853-869

Pain associated with injection of botulinum a exotoxin reconstituted using isotonic sodium chloride with and without preservative.

Arch Dermatol. 138: 510Baizabal-Carvallo J.F. Jankovic J. Pappert E.

Flu-like symptoms following botulinum toxin therapy.

Toxicon. 58: 1-7Silberstein S.D. Dodick D.W. Lindblad A.S. et al.

Chronic Migraine Treatment Trial Research Group. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine.

Neurology. 78: 976-984

Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study.

Anesth Pain Res. 4: 1-4Armanious M. Khalil N. Lu Y. et al.

Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis.

J Pain Palliat Care Pharmacother. 35: 1-6Cohen F. Armand C. Lipton R.B. et al.

Efficacy and tolerability of calcitonin gene-related peptide targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine.

Pain Med. 22: 1857-1863Blumenfeld A.M. Frishberg B.M. Schim J.D. et al.

Real-World evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review.

Pain Ther. 10: 809-826Blazek A. Dafer R. Rhyne C. et al.

Combined Prophylactic treatment of chronic migraine with OnabotulinumtoxinA and Anti-CGRP monoclonal antibodies (P14-2.001).

Neurology. 98: 14Silberstein S.D. Calhoun A.H. Lipton R.B. et al.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study.

Neurology. 87: 529-538

Update of neuromodulation in chronic migraine.

Curr Pain Headache Rep. 25: 71Diener H.-C. Agosti R. Allais G. et al.

Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

Lancet Neurol. 6: 1054-1062Ching J. Tinsley A. Rothrock J.

Prognosis following discontinuation of OnabotulinumA Therapy in "Super-responding" Chronic Migraine Patients.

Headache. 59: 1279-1285Raffaelli B. Terhart M. Overeem L.H. et al.

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.

Cephalalgia. 42: 326-334